A Phase 1, Open Label, Dose Escalation Study Evaluating the Safety and Pharmacokinetics of Enteric Coated D-3263 Hydrochloride in Subjects With Advanced Solid Tumors.
Latest Information Update: 09 May 2012
At a glance
- Drugs D 3263 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 01 May 2012 Actual end date changed from Dec 2011 to Apr 2012 as reported by ClinicalTrials.gov.
- 01 May 2012 Actual patients number is 23 as reported by ClinicalTrials.gov.
- 01 Dec 2011 Status changed from active, no longer recruiting to completed.